Consequences to hearing during the conservative management of vestibular schwannomas.
OBJECTIVE
To estimate the risk of loss of serviceable hearing during the conservative management of vestibular schwannomas.


METHODS
Retrospective case review.


METHODS
Twenty-five patients with a radiological diagnosis of unilateral vestibular schwannoma were managed conservatively for a mean duration of 43.8 months (range, 12-194 mo). The pure-tone average (PTA) (0.5, 1, 2, and 3 kHz) and speech discrimination scores (SDS) were measured at regular intervals throughout the entire duration of follow-up. Serviceable hearing was defined using two criteria: 70% SDS/30 dB PTA (the 70/30 rule) and 50% SDS/50 dB PTA (the 50/50 rule). The size and growth rate of tumors were determined according to the American Academy of Otolaryngology-Head and Neck Surgery guidelines (1995). Intervention was recommended if there was evidence of continuous or rapid radiological tumor growth, and/or increasing symptoms or signs suggestive of tumor growth.


RESULTS
The risk of loss of serviceable hearing for the total group was 43% using the 70/30 rule and 42% using the 50/50 rule. Tumor growth was considered significant (> 1 mm) in 8 tumors (32%) and nonsignificant in 17 (68%). The risk of loss of serviceable hearing for the tumor-growth group was 67% using the 70/30 rule and 80% using the 50/50 rule. In contrast, the risk of loss of serviceable hearing for the no tumor-growth group was 25% using the 70/30 rule and 14% using the 50/50 rule. No audiological factors predictive of tumor growth were identified.


CONCLUSIONS
There is a significant risk of loss of serviceable hearing during the conservative management of vestibular schwannomas. This risk appears to be greater in tumors that demonstrate significant growth.
Walsh
R M
RM
Department of Otolaryngology, University Health Network, Toronto General Hospital, University of Toronto, Ontario, Canada.
Bath
A P
AP
Bance
M L
ML
Keller
A
A
Rutka
J A
JA
D000328:Adult; D001301:Audiometry, Pure-Tone; D004428:Ear Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D005260:Female; D034381:Hearing Loss / Q000209:etiology*; D006801:Humans; D007759:Labyrinth Diseases / Q000150:complications* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009464:Neuroma, Acoustic / Q000150:complications* / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D014722:Vestibule, Labyrinth